ASM Global Enters Into New Strategic Partnership With Leading Guest Experience Innovators Forward Associates
11.7.2023 17:36:00 EEST | Business Wire | Press release
As the guest experience evolves in arenas, stadiums and theaters around the world, and demand from fans for elevated and enhanced live entertainment continues to increase, ASM Global has entered into a new, strategic partnership with multidisciplinary venue strategist Forward Associates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711902751/en/
Photo courtesy of ASM Global
ASM Global President and CEO Ron Bension said, “As we continue to embrace cutting-edge technologies and industry disruptors on a global scale, producing renowned content through our unmatched relationships, culinary artistry, sustainability solutions and client profitability, we’re creating a new intersection that fuses these attributes together. Now we are investing in the industry’s leading innovators of guest experience, Forward Associates, who we’ll work with to bring all of this to life, looking at the guest journey, reimagining it for everyone and ensuring there is an even wider choice for the entire audience.”
Forward Associates, founded in 2015, is a fast-growing and dynamic team, with offices in London, Milan and Helsinki and is in the process of opening a home office in the U.S. As venues adopt an increasing focus on the guest experience, Forward Associates CEO Roy Westwood utilizes a unique and holistic approach to the guest journey and live experience, broadening the variety of venue offerings and exploring new and creative ways to elevate this for every single guest.
Forward Associates — wide-ranging experiences and areas of specialism ranging from architecture to interior design, venue strategy to premium seat sales and marketing — provides a unique “one-stop shop” to evaluate, plan, design, execute and commercialize world-class venues across the globe.
Currently, Forward Associates is shaping the next generation of hospitality at Everton FC’s new stadium, from the inception of the “All” master brand, which seeks to rebalance traditional football hospitality to the delivery of a state-of-the-art sales showroom in Liverpool’s iconic Liver Building.
Forward Associates is also working alongside the ASM Global team at Stockholm Live developing the future strategy for their portfolio of venues including the Avicii Arena. They have also been instrumental in supporting the new, transformative design at the AO Arena in Manchester as it undergoes a major $75 million redevelopment and have completed projects for ASM Global venues in the U.S. including Desert Diamond Arena in Glendale, Arizona. Other transformative projects Forward Associates has undertaken include The O2, Tottenham Hotspur, Aston Villa FC, as well as Koko and the Brighton Dome, creating multifaceted offers that deliver real, increased commercial returns.
The move demonstrates ASM Global’s continued goal: To elevate the experience for all its 165 million customers around the world and to remain the world leader in live entertainment.
Chris Bray, president of ASM Global Europe, said, “Demand for market-leading, cutting-edge guest experience is increasing at pace. Our teams are exceptional at what they do, and we need to continue to innovate in this space, always exceeding our guest expectations. Forward Associates are best in class, with a real vision for the future of live entertainment experience, and absolute expertise in their field. They provide a unique, multidisciplinary service with a proven track record of delivering exceptional concepts from start to finish. We’re delighted to enter this new partnership, which will further cement our position as market leaders in venue operations and providers of live entertainment.”
Roy Westwood added, “Whether a new build or a repositioning as part of a master-planning exercise, Forward Associates is proud to be the leader in guest experience innovation. Together with ASM Global, we have a shared vision to continually evolve in this space, with a commitment to always delivering the very best for live entertainment fans. With ASM Global’s international portfolio and reach, this is an exciting move for us; and we are very much looking forward to getting started.”
The partnership will bolster ASM Global and Forward Associates’ combined commitment to bringing innovative approaches to the future of the fan experience specifically focusing on ASM Global’s vast portfolio of the world’s most iconic venues in the live entertainment, trade show, hospitality and sports spaces.
ABOUT ASM GLOBAL
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, performing arts venues, and convention and exhibition centers, including The Moscone Center, San Francisco; ICC Sydney, Australia; Olympia London; Shenzhen World Exhibition and Convention Center, China; and P&J Live in Aberdeen, U.K. Follow us on Facebook, Instagram, LinkedIn and Twitter. asmglobal.com.
ABOUT FORWARD ASSOCIATES
As a multidisciplinary venue specialist, Forward Associates understand how different spaces and brands can act in different ways to maximize the commercial possibilities of your venue.
They work predominantly within the sports and leisure sector but take inspiration from everywhere. They create high-street ready concepts that transform what was previously thought possible in a host of mass-population venues, from stadiums, arenas and leisure attractions to hotels and shopping centers. Their work takes them to every continent but can be seen closer to home, informing Europe’s most revered new stadium developments — Tottenham Hotspur and Everton Football Club.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711902751/en/
Contact information
MEDIA CONTACTS:
Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
818-264-6812
Alex Sutton
ASM Global UK/EU
alex@galapr.co.uk
+44 7834 284401
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom